NCT05052554View on ClinicalTrials.gov

Study With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium Molecular Biomarker(s) in Subjects With FECD3

PHASE1WithdrawnINTERVENTIONAL

0

Timeline

Start Date

August 10, 2021

Primary Completion Date

April 12, 2022

Study Completion Date

April 12, 2022

Conditions

Fuchs Endothelial Corneal DystrophyFECD3Corneal DiseasesLRSDescemet's Membrane Disorder

Interventions

DRUG

QR-504a

Intravitreal (IVT) injection

Trial Locations (1)

Unknown

Moorfields Eye Hospital, NIHR Clinical Research Facility, London

Sponsors

Lead Sponsor

ProQR Therapeutics

All Listed Sponsors

lead

ProQR Therapeutics

INDUSTRY

NCT05052554 - Study With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium Molecular Biomarker(s) in Subjects With FECD3 | Biotech Hunter | Biotech Hunter